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background:  Atrial fibrillation (AF) poses a huge healthcare burden. Electrical cardioversion (DCCV) has been an effective rhythm control 
therapy for AF. We sought to examine the use of DCCV in patients with AF and to identify predictors for undergoing DCCV.
Methods:  We identified patients with a primary discharge diagnosis of AF (ICD 427.3) and primary procedure code for atrial cardioversion 
(ICD 99.61) in the year 2010 from the Nationwide Inpatient Sample. Demographic predictors of undergoing DCCV were evaluated using 
multivariate logistic regression. Statistical analysis was done using SAS v9.3 (Cary Institute Inc., Cary, NC).
results:  A total of 406,236 AF hospitalizations were identified in 2010, of which 371,718 were included for analysis after accounting for 
missing data. Rate of DCCV among AF hospitalizations was 4.2% (n=15,663). In-hospital mortality (0.3% vs 1%; p<0.01), length of stay in 
days (3.2 vs 3.5; p<0.001) and hospitalization charges (20,821$ vs 29,830$; p<0.001) were significantly lower for patients who underwent 
DCCV. Age < 40 years, male sex, Caucasian race and having private insurance were independent predictors of receiving DCCV therapy for 
AF (table).
Conclusion:  DCCV is an effective therapy for AF with a positive impact on in-hospital mortality, length of stay and hospitalization charges. 
There is a significant disparity in the utilization of DCCV based on age, sex, race and payer status. Further research can help identify 
barriers to DCCV therapy in patients with AF.
Variable Odds Ratio (95% CI) of undergoing DCCV p
Age 0.0005
18 - 39 years 1.00 (ref)
40 - 65 years 0.94 (0.771-1.145)
> 65 years 0.721 (0.574-0.907)
Sex <0.0001
Women 1.00 (Ref)
Men 1.235 (1.131-1.348)
Race 0.0003
White 1.00 (Ref)
Black 0.624 (0.493-0.789)
Others 0.746 (0.581-0.958)
Payer status <0.0001
Private Insurance 1.00 (Ref)
Medicare 0.779 (0.686-0.885)
Medicaid 0.668 (0.502-0.889)
